Spruce Biosciences Accounts Payable

Spruce Biosciences (SPRB) currently reports a accounts payable of $2.7M as of March 2026. That compares with $1.9M in the prior-year period — up 42.8% year over year. Use the charts on this page to explore Spruce Biosciences's accounts payable history and peer comparisons.

Spruce Biosciences's accounts payable increased from $1.9M to $2.7M — a 42.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Spruce Biosciences reported $2.7M in accounts payable as of March 2026. That compares with $1.9M in the prior-year period — up 42.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Spruce Biosciences, and consider following SPRB for alerts when major investors trade the stock.

Spruce Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $2.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRB with unrelated industries.